Shilpa Medicare has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur in the state of Karnataka. The authority had conducted inspection during the period July 22, 2019 to July 26, 2019.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
